eflornithine

(redirected from Vaniqa)

eflornithine

 [ef-lor´nĭ-thēn″]
an inhibitor of the enzyme catalyzing the decarboxylation of ornithine; used topically as the hydrochloride salt to reduce unwanted facial hair in females. It has also been administered intravenously in treatment of African trypanosomiasis.

eflornithine

/ef·lor·ni·thine/ (DMFO) (ef-lor´nĭ-thēn″) an inhibitor of the enzyme catalyzing the decarboxylation of ornithine; used topically as the hydrochloride salt to reduce unwanted facial hair in females.

eflornithine

An antiprotozoal drug used to treat Pneumocystis carinii pneumonia and African TRYPANOSOMIASIS. The drug is on the WHO official list.

eflornithine

an antiprotozoal agent, used as the hydrochloride in trypanosomiasis and pneumocystiscarinii pneumonia.
References in periodicals archive ?
Once the product is launched in Q2 2016, Beteflam is expected to be our fourth marketed product in Canada behind Epuris, Vaniqa, and Actikerall(TM).
SkinMedica's primary prescription product is VANIQA (eflornithine hydrochloride) Cream, 13.
The purchase agreement involved the acquisition by Women's First Healthcare of product rights, trademarks, patents, and legal filings for Vaniqa cream, as well as all related products, and over-the-counter rights.
Food and Drug Administration (FDA) approved Vaniqa (eflornithine hydrochloride), a prescription medication cream that reduces unwanted facial hair.
Mathes ran the clinical trials of Vaniqa, a drug that slows hair growth by interfering with the formation of amino acids needed for cell growth.
Vaniqa is a prescription drug approved for the cosmetic treatment of unwanted facial hair in women.
In 2007 the Group divested a portfolio of non-core products, including SOLARAZE and VANIQA, to Laboratorios Almirall ('Almirall') and sold EQUETRO and transferred post-approval study commitments to Validus Pharmaceuticals Inc.
9% cream under the trade name Vaniqa by Bristol-Myers Squibb and the Gillette Co.
The firm also manufactures Vaniqa Cream, the only FDA-approved prescription product for the reduction of unwanted facial hair in women.
3TC (lamivudine) (trademarks of GlaxoSmithKline (GSK)) COMBIVIR (lamivudine) (trademark of GSK) DYNEPO (epoetin delta) (trademark of Sanofi Aventis) EPIVIR (lamivudine) (trademark of GSK) EPZICOM (lamivudine) (trademark of GSK) JUVISTA (trademark of Renovo) PENTASA (mesalamine) (trademark of Ferring) RAZADYNE (galantamine) (trademark of Johnson & Johnson) RAZADYNE ER (galantamine) (trademark of Johnson & Johnson) REMINYL (galantamine) (trademark of Johnson & Johnson, excluding UK and Republic of Ireland) REMINYL XL (galantamine) (trademark of Johnson & Johnson, excluding UK and Republic of Ireland) SOLARAZE (diclofenac sodium (3%w/w)) (trademark of Almirall) VANIQA (eflornithine hydrochloride) (trademark of Almirall) ZEFFIX (lamivudine) (trademark of GSK)
Because there are no studies in pregnant women, the risk-benefit ratio of using Vaniqa during pregnancy "should be weighed carefully with serious consideration for either not implementing or discontinuing" the use of the product, the labeling says.